Robert Azelby - 19 Jun 2026 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Reporting relationship: Director
Issuer ticker: TNGX
Reported as of: 19 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2026, 18:10:39 UTC
Prior SEC filing: 03 Jun 2026
Next SEC filing: 01 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Julie Fogarty, as attorney-in-fact

Key filing fact

Robert Azelby filed Form 4 for Tango Therapeutics, Inc. (TNGX) on 23 Jun 2026.

Key facts

This page summarizes Robert Azelby's Form 4 filing for Tango Therapeutics, Inc. (TNGX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2026, 18:10.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001656998 Primary reporting owner

Azelby Robert

Relationship: Director
Address: C/O TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON
Signature: /s/ Julie Fogarty, as attorney-in-fact
Signature date: 23 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNGX transaction

Common Stock

Award

Transaction value
Shares: +5,740
Change %
Price: $0.000000^*
Shares after: 5,740
Date: 19 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNGX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +35,910
Change %
Price: $0.000000^*
Shares after: 35,910
Date: 19 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,910
Exercise price: $27.97
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Footnote F2

This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.